(±)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: Novel dopamine D1 receptor antagonists

Journal of Medicinal Chemistry

Volumn 39, Issue 17, 1996, Pages 3423-3428

  Shah, Jamshed H ^a   Kline, Richard H ^a   Geter Douglass, Beth ^a   Izenwasser, Sari ^a   Witkin, Jeffrey M ^a   Newman, Amy Hauck ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZAZEPINE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; BENZAZEPINE DERIVATIVE; CINNAMIC ACID DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; TRITIUM;

ARTICLE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BLOCKING; ANIMAL; CAUDATE NUCLEUS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; KINETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PUTAMEN; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ADENYLATE CYCLASE; ANIMALS; BENZAZEPINES; CAUDATE NUCLEUS; CINNAMATES; DOPAMINE ANTAGONISTS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PUTAMEN; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP; TRITIUM;

EID: 0029664816     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960143p     Document Type: Article

References (26)

1. Seeman, P.; Van Toi, H. H. M. Dopamine Receptor Pharmacology. TIPS 1994, 15, 264-270.
2. Kaiser, C.; Jain, T. Dopamine Receptors: Functions, Subtypes and Emerging Concepts. Med. Res. Rev. 1985, 5, 145-229.
3. Spealman, R. D.; Bergman, J.; Madras, B. K.; Kamien, J. B.; Melia, K. F. Role of D1 and D2 Dopamine Receptors in the Behavioral Effects of Cocaine. Neurochem. Int. 1992, 20 (Suppl.), 147S-152S.
4. Koob, G. F. Dopamine, Addiction and Reward. Semin. Neurosci. 1992, 4, 139-148.
5. Waddington, J. L. Functional Interactions Between D-1 and D-2 Dopamine Receptor Systems: Their Role in the Regulation of Psychomotor Behavior, Putative Mechanisms, and Clinical Relevance. J. Psychopharmacol. 1989, 3, 54-63.
6. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The Dopamine Hypothesis of the Reinforcing Effects of Cocaine. Trends Neurosci. 1991, 14, 299-302.
7. Kebabian, J. W.; Calne, D. B. Multiple Receptors for Dopamine. Nature (London) 1979, 277, 93-96.
8. 2 classification. TIPS 1990, 11, 231-236.
9. Civelli, O.; Bunzow, J. R.; Grandy, D. K. Molecular Diversity of the Dopamine Receptors. Annu. Rev. Pharmacol. Toxicol. 1993, 32, 281-307.
10. Gingrich, J. A.; Caron, M. G. Recent Advances in the Molecular Biology of Dopamine Receptors. Annu. Rev. Neurosci. 1993, 16, 299-321.
11. Sokoloff, P.; Schwartz, J.-C. Novel Dopamine Receptors Half a Decade Later. TIPS 1995, 16, 270-275.
12. Waddington, J. L.; O'Boyle, K. Drugs Acting on Brain Dopamine Receptors: A Conceptual Re-evaluation Five Years After the First Selective D-1 Antagonist. Pharmacol. Ther. 1989, 43, 1-52.
13. Iorio, L. C.; Barnett, A.; Leitz, F. H.; Houser, V. P.; Korduba, C. A. SCH 23390, A Potent Benzazepine Antipsychotic with Unique Interactions on the Dopaminergic Systems. J. Pharmacol. Exp. Ther. 1983, 226, 462-468.
14. 1 Dopamine Receptors; Breese, G. R., Creese, I., Eds.; Plenum Press: New York, 1986; pp 1-14.
15. Strange, P. G. New Insights into Dopamine Receptors in the Central Nervous System. Neurochem. Int. 1993, 22, 223-236.
16. 1 Receptors Depends on Intrinsic Activity. Neuropharmacology 1992, 31, 177-183.
17. Snyder, S. E.; Aviles-Garay, F. A.; Chakraborti, R.; Nichols, D. E. Watts, V. J.; Mailman, R. B. Synthesis and Evaluation of 6,7-Dihydroxy-2,3,4,8,9,13b-hexahydro-1H-benzo[6,7]cyclohepta[1,2,3-ef][3] benzazepine, 6,7-Dihydroxy-2,3,4,8,9,12b-hexahydroanthra-[10,4a,4-c,d]azepine, and 10-(Aminomethyl)-9,10-dihydro-1,2-dihydroxyanthracene as Conformationally Restricted Analogs of β-Phenyldopamine. J. Med. Chem. 1995, 38, 2395-2409.
18. 1 Receptor Agonists and Antagonists of the Benzazepine Series. J. Med. Chem. 1999, 33, 2197-2204.
19. Minor, D. L.; Wyrick, S. D.; Charifson, P. S.; Watts, V. J.; Nichols, D. E.; Mailman, R. B. Synthesis and Molecular Modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and Related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 Dopamine Antagonists. J. Med. Chem. 1994, 37, 4317-4328.
20. 1 Receptor Antagonists. J. Med. Chem. 1995, 38, 4284-4293.
21. Acri, J. B.; Shah, J. H.; Newman, A. H.; Belov, Y. P.; Basile, A. S.; Sharpe, L. G.; Witkin, J. M. Behavioral Effects and Dopamine Antagonist Properties of N-Alkylaminobenzazepines. Drug Dev. Res. 1996, 37, 39-47.
22. Weinstock, J.; Hieble, J. P.; Wilson, J. W. The Chemistry and Pharmacology of 3-Benzazepine Derivatives. Drugs Future 1985, 10, 646-697.
23. 1 dopamine receptor: Synthesis and Characterization of R-(+) and S-(-)-enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-Bromo- analogue. J. Med. Chem. 1992, 35, 1466-1471.
24. SYBYL version 6.2 available from Tripos, 1699 S. Hanley Rd., Suite 303, St. Louis, MO 63144.
25. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
26. MOPAC 6.0 available from Quantum Chemistry Program Exchange #455.